Search Results 861-870 of 18962 for Neutrophil

1. Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma - Mayo Clinic

   Peripheral absolute neutrophil count (ANC) ≥ 1000/uL; Platelet count ≥ 100,000/uL (transfusion independent); Hemoglobin ≥ 10.0 g/dL (may receive red blood ...

2. Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer - Mayo Clinic

   absolute neutrophil count ≥1,500/mcL; platelets ≥100,000/mcL; total bilirubin <1.5 X upper normal institutional limit; AST(SGOT)/ALT(SGPT) ≤2.5 X ...

3. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3 (without transfusion or growth factor support within 14 days prior to registration). Participants with ...

4. Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL. 10. Platelets ≥ 100,000/mcL. 11. Total bilirubin ≤ 2 x ULN. (≤ 3 x ULN for potential subjects with Gilbert's

5. A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma - Mayo Clinic

   Absolute neutrophil count (ANC) <1,000/μL;; Platelet count < 75,000/μL for Part 1. For Part 2; platelet count < 75,000/μL for subjects in whom < 50% of bone ...

6. Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer - Mayo Clinic

   Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL; Hemoglobin >= 10 g/dL; Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) ...

7. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair - Mayo Clinic

   Absolute neutrophil count (ANC) >= 1500 mm^3; Platelet count >= 100,000 mm^3; platelets >= 75,000 required for patients who received cycle 1 of mFOLFOX6 ...

8. SC16LD6.5 in Recurrent Small Cell Lung Cancer - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; Platelet count ≥ 100 x 109/L; Hemoglobin ≥ 9.0 g/dL; Serum bilirubin < 1.5 x ULN; AST/ALT (SGOT/SGPT) < 2.5 x ...

9. Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer - Mayo Clinic

   Participation eligibility · Absolute neutrophil count ≥ 1,500/mcL · Platelets ≥ 100,000/mcL · Hemoglobin ≥ 9.0 g/dL · Total bilirubin ≤ 1.5 x IULN · AST(SGOT)/ ...

10. Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma - Mayo Clinic

    Peripheral absolute neutrophil count (ANC) >= 1000/uL; Platelet count >= 75,000/uL (transfusion independent); Hemoglobin >= 8.0 g/dL (may receive red blood ...